New cancer drug HLX316 enters first human tests
NCT ID NCT07541534
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can shrink tumors, focusing on ovarian and related cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX316 (a protein that targets a tumor marker and helps the immune system attack cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors, especially ovarian cancer.
What could go wrong
This is a very early, small Phase I trial with only 41 people. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing Cancer Hospital
NOT_YET_RECRUITINGChongqing, China
-
Hubei Cancer Hospital
NOT_YET_RECRUITINGWuhan, China
-
Jinan Central Clinical College of Shandong First Medical University
NOT_YET_RECRUITINGJinan, China
-
Obstetris &Gynecology Hospital of Fudan University
NOT_YET_RECRUITINGShanghai, China
-
Shandong Cancer Hospital
RECRUITINGJinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••